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A b s t r a c t
Introduction: Spontaneous recanalization of the infarct-related artery (IRA) in ST-segment elevation myocardial infarction 
(STEMI) before primary angioplasty (PCI) improves clinical outcomes.
Aim: To investigate the impact of ST-segment re-elevation (reSTE) following PCI in patent IRA on left ventricular (LV) function 
recovery and remodeling.
Material and methods: Of 155 STEMI patients with patent IRA, 19 (12.3%) patients with TIMI-2 (T2
Res) and 85 (54.8%) with 
TIMI-3 (T3
Res) had further STE resolution following PCI, 20 (12.9%) with TIMI-3 did not require PCI (T3noPCI) and 31 (20.0%) with TIMI-
2/3 had reSTE of ≥ 1 mm following PCI as compared with pre-PCI recordings (T23
reSTE). LV ejection fraction (LVEF, %) and LV end-diastol-
ic and end-systolic volume indexes (LVEDVI, LVESVI, ml/m2) were measured by echocardiography 2 days and 6 months following PCI.
Results: In 6-month observation the improvement of LVEF in T3
Res (by 3.9 ±5.1%) and in T3noPCI (by 5.7 ±6.1%) patients was 
higher as compared with T23
reSTE (0.2 ±7.0%, p < 0.05 versus both). LVEDVI increased in T23reSTE patients by 6.6 ±12.6 ml/m
2, but de-
creased in T3
Res by 3.8 ±9.7 ml/m
2 and in T3noPCI by 2.4 ±6.2 ml/m
2 (for both p < 0.05 vs. T23reSTE). LVESVI increased in T23reSTE patients 
(by 3.8 ±10.8 ml/m2), did not change in T2Res (by 0.1 ±9.0 ml/m
2), but decreased in T3Res (by 4.2 ±7.2 ml/m
2, p < 0.05 vs. T23reSTE) and 
in T3
noPCI patients (by 4.7 ±7.7 ml/m
2, p < 0.05 vs. T23reSTE). ReSTE was an independent predictor of LVEF, LVEDVI and LVESVI changes 
(p < 0.001 for all).
Conclusions: ReSTE following PCI in a patent IRA is associated with a lack of improvement of LV contractility and subsequent 
LV remodeling.
Key words: acute myocardial infarction, primary percutaneous coronary intervention, ST-segment elevation.
S u m m a r y
The current study constitutes one of the infrequent reports regarding the clinical relevance of ST-segment re-elevation 
(reSTE) following primary percutaneous coronary intervention (PCI) in patients with a spontaneously recanalized infarct-relat-
ed artery (IRA). We found that reSTE was independently associated with both lack of improvement of global and infarct- 
related contractility as well as increase of left ventricular (LV)  volumes in 6-month observation. Moreover, the procedure 
accompanied by reSTE was related to worse LV function and structure recovery as compared with patients with subsequent 
ST-segment resolution following PCI. Our findings provide evidence that myocardial injury reflected by reSTE is associated 
with the loss of beneficial effects of spontaneous IRA reperfusion on subsequent LV remodeling. Further studies on therapies 
to prevent reSTE following primary PCI are necessary.
Introduction
Spontaneous reperfusion characterized by a  patent 
epicardial infarct-related artery (IRA) on initial angiogra-
phy improves the prognosis in patients with myocardial 
infarction (MI). This phenomenon affects up to 30% of 
patients with ST-segment elevation myocardial infarction 
(STEMI) [1]. Based on the results of recent EUROMAX 
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[2] and HORIZONS-AMI [3] trials, baseline thrombolysis 
in myocardial infarction (TIMI) 2 or 3 flow derived from 
spontaneous reperfusion was associated in contempo-
rary practice with a higher rate of final TIMI 3 flow grade, 
decreased frequency of adverse cardiovascular events 
and reduced short- and long-term mortality. Similar ben-
eficial effects were found with pharmacological reperfu-
sion prior to percutaneous coronary intervention (PCI) 
[4]. According to the current guidelines [5] in patients 
with spontaneously normalized ST-segment elevation, 
angiography within 24 h is recommended. Moreover, re-
cent studies showed that deferred PCI in spontaneously 
reperfused STEMI patients was associated with similar 
infarct size [6] and clinical outcomes [1, 6] as compared 
with immediate PCI.
The fourth universal definition of MI focused on the 
issue of myocardial damage associated with revascu-
larization procedures. The procedure-related myocardi-
al injury and MI associated with PCI (type 4a MI) were 
separated depending on the level of high-sensitivity car-
diac troponin and the presence of new ischemic chang-
es in ECG, cardiac imaging or angiographic findings of 
flow-limiting complications of PCI [7]. Previous studies 
reported that the incidence of peri-procedural MI var-
ies from 5 to 30% and is associated with an increased 
risk of death (adjusted hazard ratio (HR) = 1.20, 95% CI: 
1.04–1.39) [8]. When PCI is performed in a prothrombotic 
milieu in MI patients, it is extremely difficult to estimate 
the magnitude of myocardial injury associated with the 
procedure, while the extent of infarct-related necrosis is 
many times greater.
It was found that ST-segment re-elevation (reSTE) 
following primary PCI observed in one fifth of patients 
with anterior STEMI with an occluded IRA on initial con-
trast injection was not associated with increased infarct 
size, left ventricular (LV) function or clinical outcomes at 
1 year [9, 10]. In contrast, lack of ST-segment resolution 
or reSTE within 24 h following PCI was associated with 
increased enzymatic injury and reduced LV function [11]. 
Moreover, in STEMI patients, microvascular obstruction 
and intramyocardial hemorrhage were more frequently 
observed in contrast-enhanced cardiac magnetic reso-
nance of patients with reSTE during primary PCI [12]. Pre-
vious results also suggested that myocardial expansion 
of the infarcted portion [13] and pericarditis following MI 
may contribute to reSTE, but most of the available stud-
ies concerned patients with an occluded IRA.
Aim
We hypothesized that reSTE following primary PCI in 
a patent IRA might be associated with the loss of bene-
ficial effects of spontaneous reperfusion. We sought to 
investigate the significance of reSTE during PCI in STEMI 
patients with a  spontaneously recanalized IRA on LV 
function recovery and remodeling.
Material and methods
Of 969 consecutive STEMI patients we studied 155 
(16%) patients with a patent IRA treated in one center 
with primary PCI. The inclusion criteria were chest pain 
onset within 12 h with concomitant ST-segment eleva-
tion of ≥ 1 mm in at least 2 contiguous leads or ≥ 2 mm 
in at least 2 contiguous precordial leads in qualifying ECG 
done during the first medical contact as well as initial 
TIMI 2 or 3 flow in the IRA on initial contrast injection 
during angiography. The exclusion criteria were cardio-
genic shock on admission, previous coronary artery by-
pass surgery, history of malignancy, venous thromboem-
bolism, liver injury (alanine aminotransferase > 1.5 ULN), 
serum creatinine > 177 µmol/l and current oral antico-
agulation.
At first medical contact all patients received 300 mg of 
aspirin; 114 (73.5%) of them were loaded with 600 mg of 
clopidogrel and 88 (56.8%) received an intravenous bolus 
of 5000 IU of unfractionated heparin (UFH). On admis-
sion, hemoglobin, red blood cell count, white blood cell 
count, platelet count, glucose, creatinine, and high-sen-
sitivity C-reactive protein were determined by routine 
laboratory techniques. Immediately before PCI, patients 
received a weight-adjusted bolus of UFH to achieve ac-
tivated clotting time of 200–250 s. During primary PCI, 
12 patients received abciximab as a bailout procedure. 
The Export Aspiration Catheter (Medtronic Inc., Minne-
apolis, Minnesota, USA) was used in 35 (22.6%) patients. 
The study protocol complying with the Declaration of 
Helsinki was approved by the Ethics Committee of the 
Jagiellonian University. All subjects gave informed con-
sent for their participation in the study.
ECG
Standard 12-lead ECGs (25 mm/s) obtained at the 
first medical contact (qualifying ECG (Q)), before PCI (B) 
and immediately after the procedure (A) were analyzed. 
The sum of ST-segment elevations in all leads (SST) was 
measured at the J point by a single investigator blinded 
to the clinical and angiographic findings. If the sum of 
STE following PCI was higher by at least 1 mm as com-
pared with pre-PCI recordings, this patient was classified 
as re-elevated. Resolution of ST-segment elevation be-
tween qualifying ECG and ECG performed before (STRB) 
and after (STRA) primary PCI was calculated according to 
the formulas: STRB = 100%*(SSTQ – SSTB)/SSTQ and STRA 
= 100% × (SSTQ – SSTA)/SSTQ.
Angiography analysis
Angiogram analysis was performed off-line for the 
determination of the IRA, epicardial blood flow, throm-
bus burden and distal embolization, based on visu-
al inspection. Epicardial blood flow was evaluated by 
means of the TIMI flow scale [14], myocardial perfusion 
was scored according to the TIMI myocardial perfusion 
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grades (TMPG) [15] and thrombus burden was assessed 
according to the TIMI thrombus grades [16], all before 
and after primary PCI. 
In addition, angiograms were analyzed for the pres-
ence of collateral flow to the IRA or the presence of 
flow-limiting lesions in non-IRA arteries. A detailed eval-
uation was performed in two contralateral projections. 
Two experienced investigators reviewed each coronary 
angiogram in a blinded fashion. In case of a lack of agree-
ment between the two investigators, a  third one was 
sought, and a conclusion was made.
Assessment of cardiac function
Two-dimensional transthoracic echocardiography 
(TTE) was performed twice, 2 days (2D) and 6 months 
(6M) after primary PCI, at rest in a  left decubitus posi-
tion, using a Vivid S5 ultrasound machine (GE, Solingen, 
Germany) equipped with the multi-frequency harmonic 
transducer 3Sc-RS (1.3–4 MHz). All measurements were 
carried out according to joint recommendations of the 
American Society of Echocardiography and European 
Association of Echocardiography [17] by one observer 
blinded to clinical and angiographic data. Images were 
recorded in the parasternal long axis, parasternal short 
axis, apical four-chamber, apical two-chamber, and api-
cal long axis views of the LV. In apical four-chamber and 
apical two-chamber views, LV end-diastolic (LVEDV) and 
end-systolic (LVESV) volumes and ejection fraction (LVEF) 
were calculated according to the biplane Simpson meth-
od. The values of LVEDV and LVESV were subsequently 
indexed to the body surface area (LVEDVI, LVESVI [ml/
m2]). The wall motion score index was calculated for IRA 
territory (IRA-WMSI) [18]. Based on the current recom-
mendations [17], a  16-segment model for LV segmen-
tation and classification of territories supplied by each 
coronary artery were used. Wall motion of each segment 
was analyzed individually by a  trained physician and 
scored as normal or hyperkinetic – 1, hypokinetic – 2, 
akinetic – 3 and dyskinetic (or aneurysmatic) – 4. The 
function of each segment was validated in multiple views 
and the IRA-WMSI was expressed as the average value 
from all analyzed segments in the IRA territory.
Clinical outcomes
A  1-year clinical outcome included death, recurrent 
MI, and recurrent hospitalization due to symptoms of 
heart failure. Event-free survival after 1-year observation 
was defined as freedom from death, reinfarction, and re-
peated cardiovascular hospitalization.
Data were obtained from the hospital records and 
supplemented by direct and/or telephone interview with 
the patient. Cardiac function at the end of the study was 
assessed according to the New York Heart Association 
functional scale (NYHA). The NYHA functional class was 
determined by direct contact or telephone interview with 
patients.
Statistical analysis
Statistical analyses were performed with Statistica 6 
(StatSoft, Inc). Continuous variables are expressed as 
a  mean ± standard deviation or median (interquartile 
range) and categorical variables as a  number (percent-
age). Continuous variables were first checked for normal 
distribution by the Shapiro-Wilk statistic and compared 
by ANOVA when normally distributed or by the Kruskal- 
Wallis test for non-normally distributed variables, both 
with appropriate post-hoc tests. Categorical variables 
were analyzed by c2 or Fisher’s exact test. Pearson’s or 
Spearman’s rank correlation coefficients were calculated 
to test the association between two variables with a nor-
mal or non-normal distribution, respectively. Multivariate 
regression analysis was used to determine independent 
predictors of changes of LV function and remodeling. 
A p-value of less than 0.05 was considered statistically 
significant.
Results
Of 155 STEMI patients with a  patent IRA at base-
line, 19 (12.3%) patients with TIMI-2 flow (T2Res) and 85 
(54.8%) patients with TIMI-3 flow (T3Res) achieved fur-
ther STE resolution following PCI, 31 (20.0%) patients 
with TIMI-2 (n = 5) or 3 (n = 26) flow developed reSTE of 
≥ 1 mm following PCI as compared with pre-PCI record-
ings (T23reSTE) and the last 20 (12.9%) patients with base-
line TIMI-3 did not require PCI because of residual steno-
sis of less than 50% (T3noPCI).
Patients’ baseline and procedural characteristics are 
shown in Tables I and II. The studied groups did not dif-
fer in terms of demographic variables, cardiovascular risk 
factors, time of ischemia, laboratory results, IRA distri-
bution or prehospital pharmacological regimen (Table I). 
Among the compared groups, there were also no sig-
nificant differences in the thrombus burden expressed 
as TIMI thrombus grade (TTG) or distal embolization; 
however, incomplete TMGP-0/1 perfusion was more fre-
quently observed in T2Res patients before PCI and in T2Res 
and T23reSTE patients after PCI as compared with remain-
ing subgroups; therefore these patients required abcix-
imab use the most frequently (Table II).
Changes of ST-segment elevation 
Among the compared groups, there was no signif-
icant difference in the sum of STE in qualifying ECG 
(p = 0.10); however, there were significant differences 
of STE in ECGs recorded before (p = 0.005) and after PCI 
(p < 0.001) (Figure 1 A). Before PCI, STE was significantly 
higher in T2Res patients as compared with T3Res (mean 
difference: 4.0 mm, 95% CI: 0.7–7.3 mm) and T3noPCI 
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(5.0 mm, 95% CI: 0.8–0.1 mm). After PCI, residual STE 
was significantly higher in T23reSTE as compared with T3Res 
(5.0 mm, 95% CI: 3.4–6.8 mm) and T2Res (2.3 mm, 95% CI: 
0.5–5.2 mm). There were also significant differences 
of STRB (p = 0.008) and STRA (p < 0.001) (Figure 1 B). 
STRB was significantly lower in T2Res patients as com-
pared with T3noPCI (36.8%, 95% CI: 8.2–65.4%). STRA was 
significantly lower in T23reSTE as compared with both 
T3Res (36.0%, 95% CI: 24.2–47.4%) and T2Res (22.8%, 
95% CI: 6.4–39.1%).










Age [years] 56 (49–64) 57 (49–66) 61 (50–67) 59 (53–69) 0.55
Male gender 64 (75.3) 26 (83.9) 14 (73.7) 14 (70.0) 0.62
Cardiovascular risk factors:
Hypertension 52 (61.2) 15 (48.4) 14 (73.7) 11 (55.0) 0.33
Diabetes mellitus 18 (21.2) 7 (22.6) 6 (31.6) 4 (20.0) 0.99
Dyslipidemia 47 (55.3) 16 (51.6) 12 (63.2) 12 (60.0) 0.78
Smoking 55 (64.7) 19 (61.3) 13 (68.4) 14 (70.0) 0.81
Family history of coronary 
artery disease
18 (21.1) 6 (19.4) 4 (21.1) 5 (25.0) 0.91
Prior stroke 1 (1.2) 1 (3.2) 0 1 (5.0) 0.59
Peripheral artery disease 4 (4.7) 2 (6.5) 1 (5.3) 1 (5.0) 0.98
Renal failure 3 (3.5) 1 (3.2) 0 0 0.71
Previous MI 7 (11.8) 3 (9.7) 2 (10.5) 1 (5.0) 0.92
Prior PCI 5 (5.9) 2 (6.5) 0 0 0.49
Killip class on admission: 0.27
1 79 (92.9) 27 (87.0) 14 (73.7) 18 (90.0)
2 4 (4.7) 2 (6.5) 3 (15.8) 2 (10.0)
3 2 (2.4) 2 (6.5) 2 (10.5) 0
Chest pain on admission 9 (10.6) 5 (16.1) 5 (26.3) 2 (10.0) 0.30
Onset of chest pain to balloon 
inflation, min
270 (212–382) 255 (210–285) 225 (170–280) 242 (201–333) 0.11
Loading dose of clopidogrel to 
admission, min
70 (50–108) 71 (51–110) 62 (45–101) 67 (50–105) 0.42
White blood cells [×103/µl] 10.7 (9.0–13.7) 11.2 (9.2–13.8) 10.9 (9.0–13.6) 11.2 (9.2–13.8) 0.35
Hemoglobin [g/dl] 14.5 (13.4–15.2) 14.2 (13.0–14.5) 14.3 (13.2–14.7) 14.4 (13.1–14.8) 0.42
Platelet count [×103/µl] 218 (190–271) 230 (184–269) 222 (178–255) 240 (193–281) 0.57
Glucose [mmol/l] 8.4 (7.2–10.3) 7.5 (6.6–9.0) 7.7 (6.8–9.2) 7.9 (7.1–9.4) 0.23
Creatinine [µmol/l] 94 (78–105) 88 (77–103) 92 (79–105) 95 (80–107) 0.41
hs C-reactive protein [mg/l] 1.9 (1.0–6.2) 2.9 (1.7–28.6) 2.3 (1.2–8.4) 4.1 (2.7–32.6) 0.16
Hospitalization [days] 5 (3–6) 4 (3–6) 4 (3–6) 4 (3–6.75) 0.76
12-month follow-up:
Death 0 0 0 0 NA
Recurrent MI 2 (2.4) 0 0 0 0.68
Symptoms of heart failure 
(NYHA ≥ 2)
10 (11.8) 7 (22.6) 3 (15.8) 1 (5.0) 0.29
Recurrent hospitalization 
due to heart failure
4 (4.7) 2 (6.5) 2 (10.5) 1 (5.0) 0.80
Data are expressed as number (percentage) or median (interquartile range). MI – myocardial infarction, NYHA – New York Heart Association, PCI – percutaneous cor-
onary intervention, T2
Res
 – TIMI-2 flow with ST-segment resolution following PCI, T23
reSTE
 – TIMI-2/3 flow with ST-segment re-elevation following PCI, T3
noPCI
 – TIMI-3 
flow without PCI, T3
Res
 – TIMI-3 flow with ST-segment resolution following PCI.
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Aspirin, 300 mg p.o.: 1.0
Pre-hospital FMC 85 (100) 31 (100) 19 (100) 20 (100)
Clopidogrel, 600 mg p.o.: 0.65
Pre-hospital FMC 65 (76.5) 22 (71.0) 13 (68.4) 14 (70.0)
During PCI 30 (23.5) 9 (29.0) 6 (31.6) 6 (30.0)
Unfractionated heparin 0.98
Pre-hospital FMC, 5000 IU i.v. 48 (56.5) 17 (54.8) 11 (57.9) 12 (60.0)
Abciximab i.v.: 0.002
During PCI, as a bail-out procedure 2 (2.6) 6 (19.4) 4 (21.1) 0
Infarct-related artery: 0.21
Left anterior descending 35 (41.2) 18 (58.0) 12 (63.2) 10 (50.0)
Left circumflex 9 (10.6) 2 (6.5) 1 (5.3) 2 (10.0)
Right coronary artery 41 (48.2) 11 (35.5) 6 (31.5) 8 (40.0)
TIMI at baseline: NA
2 0 5 (16.1) 19 (100) 0
3 85 (100) 26 (83.9) 0 20 (100)
TIMI after PCI: 0.008
2 2 (2.4) 4 (12.9) 4 (21.1) NA
3 83 (97.6) 27 (87.1) 15 (78.9) NA
TMPG before PCI: < 0.001
0/1 3 (3.5) 4 (12.9) 8 (42.1) 4 (20.0)
2/3 82 (96.5) 27 (87.1) 11 (57.9) 16 (80.0)
TMPG after PCI: < 0.001
0/1 5 (5.9) 13 (41.9) 6 (31.6) NA
2/3 80 (94.1) 18 (58.1) 13 (68.4) NA
Distal embolization 5 (5.9) 2 (9.7) 1 (5.3) 0 0.73
TIMI thrombus grade 0.39
0–2 76 (89.4) 26 (83.9) 15 (78.9) 19 (95.0)
3–4 9 (10.6) 5 (16.1) 4 (21.1) 1 (5.0)
Data are expressed as number (percentage). FMC – first medical contact, PCI – percutaneous coronary intervention, TIMI – thrombolysis in myocardial infarction, 
TMPG – TIMI myocardial perfusion grade, T2
Res
 – TIMI-2 flow with ST-segment resolution following PCI, T23
reSTE
 – TIMI-2/3 flow with ST-segment re-elevation follow-
ing PCI, T3
noPCI
 – TIMI-3 flow without PCI, T3
Res
 – TIMI-3 flow with ST-segment resolution following PCI.
Evolution of LV systolic function
Among the compared groups, there were significant 
differences of LV ejection fraction 2 days (p = 0.001) and 
6 months following PCI (p = 0.005) (Figure 2 A). LVEF
2D 
was significantly lower in T23reSTE patients as compared 
with T3Res (mean difference: 7.4%, 95% CI: 2.5–12.3%). In 
6-month observation, LVEF increase in T3Res (by 3.9 ±5.1%) 
and in T3noPCI (by 5.7 ±6.1%) patients was higher as com-
pared with that in T23reSTE patients (0.2 ±7.0%, p < 0.05 for 
both) (Figure 2 B). At 6M, LVEF was significantly lower in 
T23reSTE as compared with T3Res (5.5%, 95% CI: 1.6–16.5%) 
and T3noPCI (3.3%, 95% CI: 6.4–39.1%). In T2Res patients, 
LVEF did not change significantly in 6-month observation.
There were also significant differences in wall motion 
score index values calculated for infarct-related terri-
tory (IRA-WMSI) both 2 days (p = 0.03) and 6 months 
following PCI (p < 0.001) (Figure 2 C). The IRA-WMSI2D 
was significantly higher in T23reSTE patients as compared 
with T3Res (mean difference: 0.25, 95% CI: 0.02–0.49). In 
6-month observation, IRA-WMSI improvement in T3Res 
(by 0.33 ±0.25) and in T3noPCI (by 0.24 ±0.29) patients was 
higher as compared with T23reSTE patients (0.08 ±0.35, 
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p < 0.05 for both) (Figure 2 D). In T2Res patients, IRA-WMSI 
did not change in 6-month observation. At 6 months, 
differences in IRA-WMSI were more pronounced and 
IRA-WMSI was significantly higher in T23
reSTE as com-
pared with T3Res (0.49, 95% CI: 0.25–0.72) and T3noPCI 
(0.36, 95% CI: 0.04–0.68). 
LV remodeling
There were no differences among the compared 
groups in terms of baseline LVEDVI (p = 0.89) and LVESVI 
(p = 0.08) (Figures 3 A, C). In 6-month follow-up, LVEDVI 
increased in T23
reSTE by 6.6 ±12.6 ml/m
2 and decreased in 
group T3
Res by 3.8 ±9.7 ml/m
2 and T3noPCI by 2.4 ±6.2 ml/m
2 
(for both p < 0.05 vs. T23
reSTE) (Figure 3 B). In T2Res pa-
tients, LVEDVI did not change significantly in 6-month 
observation. Therefore, after 6 months, LVEDVI was 
significantly higher in T23
reSTE as compared with T3Res 
(9.9 ml/m2, 95% CI: 0.6–19.3 ml/m2) (Figure 3 A).
In 6-month follow-up, LVESVI increased in T23
reSTE (by 
3.8 ±10.8 ml/m2) patients, did not change significantly in 
Figure 1. Changes of ST-segment elevation and ST-segment elevation resolution in the studied patients
Data are shown as mean and standard deviation. Q, B, A – ECG recorded at first medical contact, before and after PCI, respectively. T2
Res
 – TIMI-2 flow with 
ST-segment resolution following PCI, T23
reSTE
 – TIMI-2/3 flow with ST-segment re-elevation following PCI, T3
noPCI
 – TIMI-3 flow without PCI, T3
Res
 – TIMI-3 












































































































  T3Res    T23reSTE   T2Res  T3noPCI
 
B  A B  A B  A B
  T3Res    T23reSTE   T2Res  T3noPCI
 2D  6M 2D  6M 2D  6M 2D  6M
  T3Res    T23reSTE  T2Res   T3noPCI
 2D  6M 2D  6M 2D  6M 2D  6M
  T3Res    T23reSTE  T2Res   T3noPCI
 T3Res  T23reSTE T2Res T3noPCI
 T3Res  T23reSTE T2Res T3noPCI
Figure 2. Changes of global and infarct-related contractility of left ventricle
Data are shown as mean and standard deviation. 2D – measurements performed 2 days after PCI, 6M – measurements performed 6 months after PCI,  
LVEF – left ventricular ejection fraction, IRA WMSI – wall motion index score for infarct-related territory, T2
Res
 – TIMI-2 flow with ST-segment resolution 
following PCI, T23
reSTE
 – TIMI-2/3 flow with ST-segment re-elevation following PCI, T3
noPCI
 – TIMI-3 flow without PCI, T3
Res
 – TIMI-3 flow with ST-segment 
resolution following PCI. *P < 0.001 vs. 2D-T3
Res
, **p < 0.01 vs. 6M-T23
reSTE
, ***p < 0.05 vs. T23
reSTE
.
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T2PCI (by 0.1 ±9.0 ml/m
2) patients, whereas it decreased 
in T3Res (by 4.2 ±7.2 ml/m
2) and in T3noPCI (by 4.7 ±7.7 ml/
m2) patients (for both p < 0.05 as compared with T23reSTE) 
(Figure 3 D). Finally, after 6 months LVESVI was significant-
ly higher in T23
reSTE as compared with T3Res (13.8 ml/m
2, 
95% CI: 5.8–21.9 ml/m2) and with T3noPCI (11.5 ml/m
2, 
95% CI: 0.5–22.4 ml/m2) (Figure 3 C).
Clinical outcomes 
The time of hospitalization and the number of pa-
tients with symptoms of heart failure in the NYHA scale 
≥ 2 after 12 months were similar in all groups (Table I). 
In 12-month follow-up, there were no deaths, 2 (1.3%) 
patients had recurrent MI and 9 (5.8%) required hospital-
ization due to symptoms of heart failure. There were no 
significant intergroup differences (Table I).
Predictive value of reSTE
The multivariate models for the recovery of LV func-
tion and LV remodeling are shown in Table III. Indepen-
dent variables identified as associated (p < 0.2) with de-
pendent variables in the univariate model (Tables I, II) 
were included in the multivariate regression models. 
Moreover, significant correlations between independent 
variables including LVEF
2D and infarct territory (r = 0.31, 
p < 0.001), LVEF
2D and the incidence of reSTE (r = 0.28, 
p < 0.001), LVEDVI2D and infarct territory (r = 0.19, p = 0.011) 
and LVESVI2D and infarct territory (r = 0.40, p < 0.001) 
were found. In final multivariate models, reSTE and base-
line LVEF independently affected changes of LVEF with 
variance of R2 = 0.31 (p = 0.002) (Table III), whereas only 
reSTE independently predicted changes of both LVEDVI 
and LVESVI with variance of R2 = 0.35 and R2 = 0.36, re-
spectively (p < 0.001 for both).
Discussion
To our knowledge, the current study constitutes one 
of the infrequent reports regarding clinical relevance 
of reSTE following primary PCI in patients with sponta-
neously recanalized IRA. We demonstrated that reSTE 
was independently associated with both lack of improve-
ment of global and infarct-related contractility and in-
crease of LV volume in 6-month observation. Moreover, 
the procedure accompanied by reSTE was related to 
worse LV function and structure recovery as compared 
with patients with subsequent ST-segment resolution 
following PCI. Our findings provide evidence that myo-
cardial injury reflected by reSTE is associated with the 
loss of beneficial effects of spontaneous IRA reperfusion 
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Figure 3. Changes of left ventricular volume indexes
Data are shown as mean and standard deviation. 2D – measurements performed 2 days after PCI, 6M – measurements performed 6 months after PCI, 
LVEDVI – left ventricular end-diastolic volume index, LVESVI – left ventricular end-systolic volume index, T2
Res
 – TIMI-2 flow with ST-segment resolution 
following PCI, T23
reSTE
 – TIMI-2/3 flow with ST-segment re-elevation following PCI, T3
noPCI
 – TIMI-3 flow without PCI, T3
Res
 – TIMI-3 flow with ST-segment 
resolution following PCI. *P < 0.001 vs. 6M-T23
reSTE
, **p < 0.01 vs. 6M-T23
reSTE
, ***p < 0.05 vs. T23
reSTE
.
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Our study also provides some evidence regarding the 
mechanism of reSTE. We have shown that angiographi-
cally visible distal embolization occurred in around 10% 
of patients with reSTE and occurred in a similar propor-
tion in the remaining analyzed groups and other studies 
[19, 20]. Moreover, we found no significantly different 
distribution of TIMI thrombus grades in the compared 
groups, which suggests a  lack of unquestionable asso-
ciation between reSTE and angiographically evident re-
sidual epicardial thrombus. Simultaneously, the results of 
our study emphasize the role of impaired microvascular 
perfusion in patients with reSTE. Incomplete TMPG-0/1 
reperfusion after PCI was the most frequent in patients 
with reSTE. Moreover, in about 30% of patients with 
reSTE, myocardial perfusion was deteriorated from base-
line TMPG-2/3 to 0/1 following PCI. This observation is 
consistent with our previous findings [21] and reports 
on microvascular injury assessed with cardiac magnetic 
resonance in patients with reSTE [12]. It might be spec-
ulated that during balloon inflation, the components of 
ruptured plaque containing connective tissue elements 
and subendothelial matrix proteins are exposed to the 
bloodstream and initialize platelet activation, thrombin 
generation followed by thrombus formation and promote 
vasospasm. Prothrombotic material protruding through 
the struts during stent implantation together with the 
already present intraluminal thrombus may lead to epi-
cardial blood flow deterioration [22] and microvascular 
plugging [23]. Identification of the key factor involved in 
myocardial perfusion deterioration in patients with reSTE 
after spontaneous reperfusion requires further studies 
with the use of optical coherent tomography. Interest-
ingly, in our study reSTE was associated with a  similar 
systemic inflammatory response as measured by white 
blood cell count and hsCRP level. In contrast, a previous 
study reported that CRP concentration in STEMI patients 
with reSTE was higher, reflecting more intensified reper-
fusion injury [11].
In our group, unfavorable echocardiographic findings 
related to reSTE did not affect the duration of hospital-
ization or 1-year clinical outcomes. Research conducted 
so far regarding the impact of reSTE following PCI on LV 
function concerns mainly patients with initially occluded 
IRA. In a  small observational study including 41 STEMI 
patients, Weaver et al. [12] found a significant relation-
ship between reSTE and the extent of myocardial injury 
assessed by contrast-enhanced cardiac magnetic reso-
nance. In turn, Okuda et al. [11] revealed that reSTE in 
patients who underwent both primary PCI and thrombol-
ysis was associated with larger infarct size and poorer 
LVEF and LVEDVI at 6 months. A recently published sub-
analysis of the large randomized CIRCUS trial [9] showed 
no unfavorable effects of reSTE on LV contractility and 
remodeling at 1-year follow-up. Patients with and with-
out the reSTE primary endpoint composed of all-cause 
mortality and heart failure were found with similar pro-
portion (19.2 vs. 19.8%, p = 0.887) at 1 year. It should be 
emphasized that only patients with a large anterior wall 
infarction were included in this study, which may mask 
the effects associated with reSTE. Our findings suggest 
that the incidence of reSTE following PCI in a patent IRA 
produces the risk of LVEF deterioration on average by 
4.4% and the risk of LVEDVI or LVESVI increase by 7 or 
8.5 ml/m2, respectively.
In the context of high prevalence of impaired tis-
sue-level microvascular perfusion in patients with reSTE 
following PCI in a spontaneously reperfused IRA and its 
unfavorable long-term LV consequences, implementa-
tion of appropriate preventive and therapeutic strate-
gies seems to be a key goal. As was documented in the 
DEFER-STEMI study [24], deferred PCI in selected STEMI 
patients reduced no-reflow, distal embolization and oth-
er thrombotic complications as compared with imme-
diate stenting. However, other studies provided consid-
erably less optimistic conclusions. In DANAMI 3-DEFER 
[25], deferred PCI did not reduce the occurrence of death, 
Table III. Independent predictors of changes of LVEF, LVEDVI and LVESVI
Dependent 
variable
Independent variable Univariate model Multivariate model
Coefficient B P-value 95% CI for 
coefficient B





reSTE (Yes/No) –3.73 0.001 –6.00– –1.47 –4.35 < 0.001 –6.71– –1.99
LVEF
2D




reSTE (Yes/No) 9.25 < 0.001 5.06–13.44 8.58 < 0.001 4.32–12.84




reSTE (Yes/No) 7.47 < 0.001 4.14–10.81 7.08 < 0.001 3.63–10.54
LAD as IRA (Yes/No) 2.29 0.112 –0.54–5.11 0.95 0.514 –1.91–3.81
LVESVI
2D
 (per 1 ml/m2) 0.09 0.162 –0.04–0.22 0.03 0.660 –0.10–0.16
IRA – infarct-related artery, LAD – left anterior descending artery, LVEF – left ventricular ejection fraction, LVEDVI – left ventricular end-diastolic volume index, 
LVESVI – left ventricular end-systolic volume index, reSTE – ST-segment re-elevation following PCI, 2D – measurements performed two days after PCI, R2 – variance.
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heart failure, MI or subsequent revascularization as 
compared with conventional PCI. Moreover, routine de-
ferred stenting was associated with a higher frequency 
of target vessel revascularization. A  recent meta-analy-
sis summarizing prior randomized trials showed that the 
deferred-stenting strategy did not reduce the occurrence 
of no-reflow, death, MI or repeated revascularization 
despite improved LVEF in long-term observation [26]. 
Based on these findings, routine deferred stenting is not 
recommended in the current European Society of Cardi-
ology (ESC) guidelines [27]. Another intensively investi-
gated strategy is thrombus aspiration. The two recent 
randomized trials TASTE [28] and TOTAL [29] showed no 
clinical benefit of routine thrombus aspiration in STEMI 
patients, suggesting possible increased risk of stroke. 
A  meta-analysis of the trials TAPAS [30], TASTE and 
TOTAL finally confirmed that routine thrombus aspira-
tion in STEMI patients did not improve clinical outcomes 
[31]. This meta-analysis, however, highlighted the group 
with high thrombus burden in which use of aspiration 
thrombectomy was associated with lower cardiovascular 
mortality (HR = 0.80, 95% CI: 0.65–0.98) but also with 
increased risk of stroke or transient ischemic attack (OR 
= 1.56, 95% CI: 1.02–2.42). Based on these data, routine 
thrombus aspiration is also not recommended in current 
ESC guidelines but in cases of large residual thrombus 
burden, after opening of the IRA, thrombus aspiration 
may be considered [27]. The current guidelines of ESC, 
however, permit the application of IIb/IIIa inhibitors as 
bailout therapy in the case of large thrombus, slow- or 
no-reflow, and other thrombotic complications [27]. Fur-
thermore, a recently published study demonstrated the 
beneficial effect of early intracoronary administration of 
nicorandil on microcirculation damage [32]. Other strat-
egies aimed at reduction of reperfusion injury, including 
cyclosporine, which activates mitochondrial potassium 
channels, failed to improve clinical outcomes and pre-
vent LV remodeling [33], despite previous experimental 
studies indicating its beneficial effects on infarct size and 
microvascular obstruction [34].
Our study has several limitations. First, the sample 
size and the number of clinical adverse events are not 
large enough to draw clinical conclusions. Second, left 
ventricular remodeling was assessed by echocardiog-
raphy, although cardiac magnetic resonance is a  more 
accurate and objective method. Third, all participants 
were meticulously studied with serial ECGs only in the 
periprocedural period. Subsequent ECGs, including 60–
90 min after PCI, were not prospectively recorded. Fourth, 
platelet reactivity [35], fibrin clot properties [36] and in-
tracoronary thrombi [37] were not analyzed. However, 
these laboratory tests were beyond the main scope of 
this study.
Conclusions
ReSTE following PCI in patients with spontaneously 
recanalized IRA is associated with a lack of improvement 
of LV contractility and subsequent LV remodeling and 
therefore abolishes the beneficial effects of spontaneous 
reperfusion. Further studies on therapies to prevent 
reSTE following primary PCI are necessary.
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